CLOUDBREAK PHARMA INC. 撥 康 視 雲 製 藥 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 董事名單與其角色和職能 非執行董事 LI Jun Zhi博士 曹旭先生 夏志東先生 獨立非執行董事 聶四江女士 馬遙豪先生 李朝昌先生 董事會設立三個委員會。下表列示各董事會成員自2025年12月1日起在該委員會中所擔任的職位： | | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | Jinsong博士 NI | | | | | C | | DINH Son | Van先生 | | | | | | YANG | Rong博士 | | | | | | LI Jun Zhi博士 | | | M | M | M | | 曹旭先生 | | | | | | | 夏志東先生 | | | | | | | 聶四江女士 | | | M | C | M | | 馬遙豪先生 | | | C | M | M | | 李朝昌先生 | | | M | | M ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） (1) 獨立非執行董事辭任； (2) 委任獨立非執行董事；及 賴先生已確認：(i)彼與董事會並無意見分歧；及(ii)概無有關彼之上述辭任的其他事項須提請本公司 股東垂注。 董事會謹此對賴先生於其任期內向本公司所作貢獻表示感謝。 (3) 董事委員會成員變動 撥康視雲製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」）會（「董事會」）謹 此宣佈： 獨立非執行董事辭任 董事會謹此宣佈，賴先生已提交辭呈，辭任獨立非執行董事、提名委員會主席、審核委員會成員及 薪酬委員會成員，自2025年12月1日起生效，以便投入更多時間於其他業務安排。 1 1. 賴顯榮先生（「賴先生」）已提交辭呈，辭任獨立非執行董事（「獨立非執行董事」）、本公司提名 委員會（「提名委 ...

Core Viewpoint - The company has announced the resignation of its auditor, PricewaterhouseCoopers, effective November 27, 2025, and has appointed Guowei Certified Public Accountants as the new auditor to fill the vacancy [1]. Group 1 - PricewaterhouseCoopers has resigned as the company's auditor, effective from November 27, 2025 [1]. - Guowei Certified Public Accountants has been appointed as the new auditor based on the recommendation of the audit committee, effective from the same date [1]. - The term of Guowei will last until the conclusion of the next annual general meeting of the company [1].

Core Viewpoint - The company has announced the resignation of its auditor, PwC, effective November 27, 2025, and has appointed Guowei CPA as the new auditor to fill the vacancy left by PwC [1] Group 1 - PwC has resigned as the company's auditor, with the resignation taking effect on November 27, 2025 [1] - Guowei CPA has been appointed as the new auditor, effective from the same date [1]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 核數師辭任 本公司董事會（「董事會」）宣佈，羅兵咸永道會計師事務所（「羅兵咸永道」）已辭任本公司核數師，自 2025年11月27日起生效。 由於本公司與羅兵咸永道未能就審核本集團截至2025年12月31日止財政年度（「2025財年」）的綜合財 務報表的審核費用達成共識，應本公司要求，羅兵咸永道已同意辭任本公司核數師。 董事會及本公司審核委員會（「審核委員會」）已審閱羅兵咸永道提供的審核費用建議，並考慮到本集 團目前的經營規模、市場上其他具備必要能力及勝任資格（包括技術知識、行業知識及往績記錄、人 力及其他資源）的專業會計師事務所提供的費用，以及本集團的成本控制措施，認為建議費用未必具 競爭力。因此，董事會及審核委員會認為更換本公司核數師屬適當。 本公司根據開曼群 ...

致：香港交易及結算所有限公司 公司名稱: Cloudbreak Pharma Inc. 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02592 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | 本月底法定/註冊股本總額： USD 200,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的 ...

Core Viewpoint - The company, 拨康视云-B (02592), announced the issuance of approximately 3.888 million shares under a Series C equity incentive plan on October 30, 2025 [1] Group 1 - The share issuance is part of a broader equity incentive arrangement aimed at motivating and retaining key personnel within the company [1] - The total number of shares being issued is approximately 3.888 million [1]

Core Viewpoint - The company, Bolekang Shiyun-B (02592), announced the issuance of approximately 3.888 million shares under its Series C equity incentive plan, scheduled for October 30, 2025 [1] Group 1 - The company is set to issue around 3.888 million shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： Cloudbreak Pharma Inc. 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02592 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

Core Insights - The current state of the biopharmaceutical market shows a stark contrast between the primary and secondary markets, a situation not seen in the past five years [1] - Since 2022, the investment enthusiasm in the biopharmaceutical sector has declined, leading to challenges such as reduced R&D efficiency and insufficient commercialization [1][3] - Key areas for new development in the biopharmaceutical industry include overseas licensing, AI healthcare, and improved payment systems [1][7] Market Dynamics - The primary market is primarily funded by state-owned capital, while market-driven funds have not yet returned [2][3] - The Hong Kong stock market is becoming a significant option for biopharmaceutical companies to go public, although there is a notable disparity in market performance [2][3] - The secondary market, particularly in Hong Kong, has seen continuous growth, driven by innovative drug companies reaching the delivery stage [3] Investment Trends - The investment landscape has shifted, with a focus on companies that can demonstrate strong overseas licensing capabilities as a measure of competitiveness [7][8] - The amount of overseas licensing for domestic innovative drugs reached $25.7 billion in 2023, surpassing the amount for technology introduced from abroad [7] - By 2025, the overseas licensing amount is expected to exceed $100 billion, indicating a significant trend towards global market engagement [7] Entrepreneurial Guidance - Entrepreneurs are advised to fully commit to their ventures and develop comprehensive strategic plans to navigate the current market environment [5][6] - Effective communication between entrepreneurs and investors is crucial for capitalizing on growth opportunities [5][6] - Companies should avoid the pressure of rapid expansion and instead focus on aligning their development pace with market demands and financial conditions [6] Future Outlook - The biopharmaceutical industry is expected to benefit from policy improvements and technological advancements, creating new growth opportunities [7][8] - The ability to adapt to external policy risks, particularly in overseas markets, will be essential for companies looking to expand internationally [8] - The long-term investment horizon in the biopharmaceutical sector remains promising, despite the current challenges [8]